Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Elevance Health logoElevance Health ELV

The company said its officers will speak with investors over the next several weeks and intend to reaffirm its 2024 full-year net income outlook of greater than $34.05 per diluted share. The outlook includes about $3.15 per diluted share of net unfavorable items.

8-KRegulation FD DisclosureFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said its officers will speak with investors over the next several weeks and intend to reaffirm its 2024 full-year net income outlook of greater than $34.05 per diluted share. The outlook includes about $3.15 per diluted share of net unfavorable items.

  2. The company said it continues to expect adjusted net income, which excludes net unfavorable items, to be greater than $37.20 per diluted share.

  3. The company said the outlook does not include any adjustment items beyond those reported in its Q1 2024 earnings release.

  4. The company said the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the 1934 Securities Exchange Act and, unless expressly set forth by specific reference, is not incorporated by reference in any filing under the 1933 Securities Act.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Elevance Health Reaffirms 2024 Full-Year Net Income Outlook

The company said its officers will speak with investors over the next several weeks and intend to reaffirm its 2024 full-year net income outlook of greater than $34.05 per diluted share. The outlook includes about $3.15 per diluted share of net unfavorable items.

Source · Based on the filing body and exhibits

Adjusted Net Income Outlook Greater Than $37.20 Per Share

The company said it continues to expect adjusted net income, which excludes net unfavorable items, to be greater than $37.20 per diluted share.

Source · Based on the filing body and exhibits

Adjustment Items Included in Outlook

The company said the outlook does not include any adjustment items beyond those reported in its Q1 2024 earnings release.

Source · Based on the filing body and exhibits

Filing Status of Information Under Item 7.01

The company said the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the 1934 Securities Exchange Act and, unless expressly set forth by specific reference, is not incorporated by reference in any filing under the 1933 Securities Act.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.